Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site

The BCR/ABL1 inhibitor Nilotinib is increasingly used to treat patients with chronic myeloid leukemia (CML). Although otherwise well-tolerated, Nilotinib has been associated with the occurrence of progressive arterial occlusive disease (AOD). Our objective was to determine the exact frequency of AOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Hadzijusufovic, Emir, Albrecht-Schgoer, Karin, Huber, Kilian, Hoermann, Gregor, Grebien, Florian, Eisenwort, Gregor, Schgoer, Wilfried, Herndlhofer, Susanne, Kaun, Christoph, Theurl, Markus, Sperr, Wolfgang R., Rix, Uwe, Sadovnik, Irina, Jilma, Bernd, Schernthaner, Gerit H., Wojta, Johann, Wolf, Dominik, Superti-Furga, Giulio, Kirchmair, Rudolf, Valent, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669463/
https://www.ncbi.nlm.nih.gov/pubmed/28757617
http://dx.doi.org/10.1038/leu.2017.245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669463/
https://www.ncbi.nlm.nih.gov/pubmed/28757617
http://dx.doi.org/10.1038/leu.2017.245

Ejemplares similares